Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, discusses that the ipilimumab (Yervoy) label is very broad and includes both pretreated and untreated metastatic melanoma. No subset of patients has been identified that will not benefit from the drug. Evaluating prognostic information reveals that survival benefits has been found in all groups.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Immuno-Oncology

Immunotherapy in Melanoma

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Melanoma & Skin Cancer

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses Which Patients are Eligible to Receive Ipilimumab

Dr. Hoos Discusses Patients Eligible to Receive Ipilimumab